Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23088134 | 1.00 | AR (0.32) | ARALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL31050368 | 0.79 | — | — | |
| SCHEMBL23088461 | 0.75 | CD274 (0.39) | ARALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL23088207 | 0.75 | AR (0.38) | ARALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL29792743 | 0.75 | AR (0.38) | ARALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL16401940 | 0.70 | HTR2A (0.39) | ALDH1A1KDM4ELMNAMAPTSMN1; SMN2 | |
| SCHEMBL29407395 | 0.70 | KMT2A (0.48) | ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL17221294 | 0.70 | KMT2A (0.48) | ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL20503059 | 0.66 | PDE3B (0.37) | ALDH1A1KMT2AKDM4EMAPTHPGD | |
| SCHEMBL30849870 | 0.66 | PDE3B (0.37) | ALDH1A1KMT2AKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4031547-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |